The best initial treatment strategy for asymptomatic, advanced-stage nonbulky follicular lymphoma is "not clear," according to an editorial published in the April edition of Lancet Oncology. Watch-and ...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a ...

The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for ...

Epcoritamab plus rituximab/lenalidomide significantly improved PFS and ORR compared with rituximab/lenalidomide alone. The Food and Drug Administration (FDA) has approved Epkinly ® (epcoritamab-bysp), ...

Incyte Biosciences Japan G.K. (INCY) on Monday reported the approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide ...

Epcoritamab-bysp, combined with rituximab and lenalidomide, is FDA-approved for relapsed follicular lymphoma, marking a significant advancement in second-line treatment. The EPCORE FL-1 trial showed a ...

Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life Two hundred two patients with low–tumor burden FL were randomly assigned to the ...

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...

Although previously tested in an upfront window by the Berlin–Frankfurt–Munster group, the safety and efficacy of rituximab in combination with multiagent chemotherapy regimens in children and ...